Breast Cancer, Cancer
ALXOALX Oncology Holdings IncCatalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Evorpacept (ALX148) + Trastuzumab + Chemotherapy (CD47 Blocker) in Breast Cancer, Cancer. The expected timing is based on the latest available company guidance and may change.
11/07/25:- Phase 2 ASPEN-09 HER2+ breast cancer trial plans FPI in Q4 2025; interim data expected Q3 2026. 01/08/26:- First patient dosed in Ph2 ASPEN-09-Breast; interim data expected Q3 2026. 02/27/26:- ASPEN-09-Breast expanding to 120 patients; primary CD47-high ORR; topline data for 80 patients expected Mid-2027. 05/08/26:- ASPEN-09-Breast enrollment on track; topline data for 80 HER2+ patients still expected Mid-2027. 08/06/26:- ASPEN-09-Breast enrollment remains on track; topline data expected Mid-2027.
Verification
Confirm timing and program details against the company announcement or filing.